CR20140075A - Métodos terapéuticos - Google Patents

Métodos terapéuticos

Info

Publication number
CR20140075A
CR20140075A CR20140075A CR20140075A CR20140075A CR 20140075 A CR20140075 A CR 20140075A CR 20140075 A CR20140075 A CR 20140075A CR 20140075 A CR20140075 A CR 20140075A CR 20140075 A CR20140075 A CR 20140075A
Authority
CR
Costa Rica
Prior art keywords
therapeutic methods
hepatitis
iib
formulas
human
Prior art date
Application number
CR20140075A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR20140075A publication Critical patent/CR20140075A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para el tratamiento de Hepatitis C en un ser humano que lo necesite, el cual comprende administrar un compuesto de las fórmulas (II) o (IIB) descrito en la presente, o un sal farmacéuticamente aceptable del mismo, en combinación con uno o más agentes terapéuticos alternativos para la Hepatitis C.
CR20140075A 2011-08-17 2014-02-17 Métodos terapéuticos CR20140075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524429P 2011-08-17 2011-08-17
US201161526787P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
CR20140075A true CR20140075A (es) 2014-03-24

Family

ID=47715500

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140075A CR20140075A (es) 2011-08-17 2014-02-17 Métodos terapéuticos

Country Status (22)

Country Link
US (2) US9119868B2 (es)
EP (1) EP2744342B1 (es)
JP (2) JP6121419B2 (es)
KR (2) KR20140093209A (es)
CN (2) CN106109479A (es)
AU (1) AU2012296446B2 (es)
BR (1) BR112014003556A2 (es)
CA (1) CA2843502C (es)
CL (2) CL2014000394A1 (es)
CO (1) CO6880064A2 (es)
CR (1) CR20140075A (es)
DO (1) DOP2014000030A (es)
EA (2) EA024357B1 (es)
ES (1) ES2735542T3 (es)
IL (1) IL230484A (es)
MA (1) MA35347B1 (es)
MX (1) MX2014001833A (es)
PE (1) PE20141391A1 (es)
PH (1) PH12014500381A1 (es)
SG (1) SG10201606646RA (es)
WO (1) WO2013025992A1 (es)
ZA (2) ZA201400435B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296446B2 (en) * 2011-08-17 2015-07-09 Glaxosmithkline Llc Therapeutic methods
ES2611731T3 (es) * 2011-08-19 2017-05-10 Glaxo Group Limited Compuestos de benzofurano para el tratamiento de infecciones por el virus de la hepatitis C
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
JP7086987B2 (ja) * 2017-03-21 2022-06-20 ザ スクリプス リサーチ インスティテュート 銅およびニッケル触媒による脱炭酸ホウ素化反応
CN114929715A (zh) * 2019-10-25 2022-08-19 住友制药株式会社 新型取代稠环型化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
WO2004041201A2 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
EP1686949A2 (en) 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
ES2377280T3 (es) * 2008-02-14 2012-03-26 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) * 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
TW201221131A (en) * 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
AU2012296446B2 (en) * 2011-08-17 2015-07-09 Glaxosmithkline Llc Therapeutic methods
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
ES2611731T3 (es) * 2011-08-19 2017-05-10 Glaxo Group Limited Compuestos de benzofurano para el tratamiento de infecciones por el virus de la hepatitis C
MX2014002171A (es) * 2011-08-24 2014-04-25 Glaxosmithkline Llc Tratamientos de combinacion para hepatitis c.

Also Published As

Publication number Publication date
US20140212384A1 (en) 2014-07-31
KR20180129973A (ko) 2018-12-05
AU2012296446B2 (en) 2015-07-09
NZ619985A (en) 2016-06-24
ZA201502595B (en) 2017-01-25
PE20141391A1 (es) 2014-10-29
JP2017165732A (ja) 2017-09-21
EP2744342A1 (en) 2014-06-25
EA024357B1 (ru) 2016-09-30
IL230484A (en) 2016-11-30
EP2744342A4 (en) 2015-01-28
CN103929965B (zh) 2016-08-17
WO2013025992A1 (en) 2013-02-21
AU2012296446A1 (en) 2014-02-13
CL2014000394A1 (es) 2014-08-01
MA35347B1 (fr) 2014-08-01
US20150320777A1 (en) 2015-11-12
EA201690327A1 (ru) 2016-06-30
PH12014500381A1 (en) 2021-07-12
JP6121419B2 (ja) 2017-04-26
US9119868B2 (en) 2015-09-01
CA2843502C (en) 2019-01-15
EP2744342B1 (en) 2019-04-24
CA2843502A1 (en) 2013-02-21
CN106109479A (zh) 2016-11-16
IL230484A0 (en) 2014-03-31
US10238678B2 (en) 2019-03-26
JP2014524446A (ja) 2014-09-22
CN103929965A (zh) 2014-07-16
ES2735542T3 (es) 2019-12-19
KR101975233B1 (ko) 2019-05-07
KR20140093209A (ko) 2014-07-25
CL2016000300A1 (es) 2016-09-02
EA201490199A1 (ru) 2015-01-30
BR112014003556A2 (pt) 2017-03-21
EA201490199A8 (ru) 2015-12-30
ZA201400435B (en) 2015-09-30
SG10201606646RA (en) 2016-09-29
DOP2014000030A (es) 2014-06-30
CO6880064A2 (es) 2014-02-28
MX2014001833A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CR20140075A (es) Métodos terapéuticos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR101740A1 (es) Terapia de combinación y composiciones
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CR20130043A (es) Compuestos terapéuticos
CL2019000844A1 (es) Compuesto de piridina.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2014003180A (es) Metodos para tratar vhc.
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
MX2014015185A (es) Derivados deuterados de ruxolitinib.
MX2013013437A (es) 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
BR112015020466A2 (pt) inibidores de cdc7
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CL2016000241A1 (es) Formulación de inhibidores de la syk.
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
CO7350640A2 (es) Compuestos diméricos
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.